Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper ...

A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), ...

Three months into its U.S. launch for lupus nephritis (LN), Roche/Genentech’s Gazyva (obinutuzumab) is entering a treatment landscape shaped not only by approved agents Benlysta (belimumab, GSK) and ...

A key mystery behind one of the most common autoimmune diseases may finally have an answer. Researchers at Northwestern Medicine and Brigham and Women’s Hospital say they’ve discovered a root cause of ...

Feb 3 (Reuters) - AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an easier-to-use version of lupus therapy Saphnelo, pushing back the timeline for a ...

Patients with systemic lupus erythematosus who receive belimumab monotherapy show comparable remission rates and disease control to those who receive combination therapy with immunosuppressants.

Feb 3 (Reuters) - AstraZeneca said on Tuesday the U.S. health regulator has rejected its application for a self-injectable version of lupus drug Saphnelo, pushing back the approval timeline for a ...

Anifrolumab, a type I interferon receptor antagonist, is already approved as an intravenous (IV) therapy for SLE. The TULIP-SC trial was designed to evaluate whether a weekly subcutaneous (SC) ...

A third-year UVA student channels her experience with chronic illness into a drive to strengthen communities through design.

Because lupus can come with so many variables and a high degree of complexity, many people get frustrated in their journeys toward managing the disease. Here, 11 patients opened up about what they ...

This Black History Month, we’re centering the voices, stories, and experiences of Black lupus warriors. Throughout February, we’re sharing resources and community spaces designed to support and ...